William Blair equity capital markets managing director Kevin Eisele was quoted in Scrip, where he outlined the current M&A and IPO trends for the industry as the third quarter came to a close and investors and companies began to look ahead to 2026.

“The market in biotech is decidedly more favorable than it was a few months ago and obviously better than it’s been over the last few years,” Eisele told the publication.